Table of Contents
Journal of Biomarkers
Volume 2015, Article ID 841245, 9 pages
Research Article

Biomarkers for Detection and Monitoring of B16 Melanoma in Mouse Urine and Feces

1Department of Biomedical Engineering, Ben-Gurion University of the Negev, 84105 Beer-Sheva, Israel
2The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, and the Department of Oncology, Soroka University Medical Center, 84105 Beer-Sheva, Israel
3Division of Chemistry, Nuclear Research Center-Negev, 84190 Beer-Sheva, Israel

Received 29 September 2014; Revised 1 January 2015; Accepted 29 January 2015

Academic Editor: Nathalie Scholler

Copyright © 2015 Aviv Sever et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Melanoma is the most malignant type of skin cancer. Early detection of melanoma is thus critical for patient prognosis and survival. At present, examination by a skilled dermatologist followed by biopsy of suspicious lesions is the diagnostic gold standard. The aim of the present study was to examine an alternative and noninvasive method for the diagnosis of melanoma at an early stage. We identified and compared the volatile organic compounds (VOCs) in mouse urine and feces, before and after a subcutaneous injection of B16 melanoma cells. We identified a total of 16 VOCs in urine and 13 VOCs in feces that could serve as potential biomarkers. Statistical analysis significantly discriminated between the cancer and control groups. These results should be validated in a larger-scale animal study, after which a study could be designed in patients to develop a melanoma biomarker.